- National Comprehensive Cancer Network
NCCN Clinical Practice Guidelines in Oncology: Colon Cancer. NCCN,
Theoretical and experimental bases of intraperitoneal chemotherapy.Semin. Oncol. 1985; 12: 1-6
The resurgence of platinum-based cancer chemotherapy.Nat. Rev. Cancer. 2007; 7: 573-584
Understanding cisplatin resistance using cellular models.IUBMB Life. 2007; 59: 696-699
Principles and practice of intraperitoneal chemotherapy for ovarian cancer.Int. J. Gynecol. Cancer. 2007; 17: 1-20
Intraperitoneal carboplatin: rationale and experience.Semin. Oncol. 1992; 19: 107-113
Phase I feasibility and pharmacologic study of weekly intraperitoneal paclitaxel: a Gynecologic Oncology Group pilot study.J. Clin. Oncol. 1995; 13: 2961-2967
Phase I trial of intraperitoneal taxol: a gynecologic Oncology Group study.J. Clin. Oncol. 1992; 10: 1485-1491
Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer.N. Engl. J. Med. 1996; 335: 1950-1955
Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group.J. Clin. Oncol. 2001; 19: 1001-1007
Intraperitoneal cisplatin and paclitaxel in ovarian cancer.N. Engl. J. Med. 2006; 354: 34-43
Long-term survival advantage and prognostic factors associated with intraperitoneal chemotherapy treatment in advanced ovarian cancer: a gynecologic oncology group study.J. Clin. Oncol. 2015; 33: 1460-1466
Intraperitoneal catheter outcomes in a phase III trial of intravenous versus intraperitoneal chemotherapy in optimal stage III ovarian and primary peritoneal cancer: a Gynecologic Oncology Group Study.Gynecol. Oncol. 2006; 100: 27-32
Use and effectiveness of intraperitoneal chemotherapy for treatment of ovarian cancer.J. Clin. Oncol. 2015; 33: 2841-2847
Peritonectomy procedures.Ann. Surg. 1995; 221: 29-42
The role of hyperthermic intraperitoneal chemotherapy (HIPEC) in ovarian cancer.Oncologist. 2009; 14: 683-694
- Rodriguez Silva C.
- et al.
Are there intra-operative hemodynamic differences between the Coliseum and closed HIPEC techniques in the treatment of peritoneal metastasis? A retrospective cohort study.World J. Surg. Oncol. 2017; 15: 51
- Giovanella B.C.
- Stehlin J.S.
- Morgan A.C.
Selective lethal effect of supranormal temperatures on human neoplastic cells.Cancer Res. 1976; 36: 3944-3950
- Hettinga J.
- Konings A.
- Kampinga H.
Reduction of cellular cisplatin resistance by hyperthermia—a review.Int. J. Hyperth. 1997; 13: 439-457
Effects of temperature on the interaction of cisplatin and carboplatin with cellular DNA.Biochem. Pharmacol. 1993; 46: 1229-1237
- Los G.
- Van Vugt M.
- Pinedo H.
Response of peritoneal solid tumours after intraperitoneal chemohyperthermia treatment with cisplatin or carboplatin.Br. J. Cancer. 1994; 69: 235
Platinum-DNA adduct in leukocyte DNA of a cohort of 49 patients with 24 different types of malignancies.Cancer Res. 1993; 53: 3694-3699
Chemotherapy delay after primary debulking surgery for ovarian cancer.Gynecol. Oncol. 2017; 144: 260-265
The time interval from surgery to start of chemotherapy significantly impacts prognosis in patients with advanced serous ovarian carcinoma - analysis of patient data in the prospective OVCAD study.Gynecol. Oncol. 2013; 131: 15-20
The cellular and molecular basis of hyperthermia.Crit. Rev. Oncol. Hematol. 2002; 43: 33-56
Mechanism of hyperthermic potentiation of cisplatin action in cisplatin-sensitive and -resistant tumour cells.Br. J. Cancer. 1997; 75: 1735-1743
Optimisation of intraperitoneal cisplatin therapy with regional hyperthermia in rats.Eur. J. Cancer. 1991; 27: 472-477
HIPEC ROC I: a phase i study of cisplatin administered as hyperthermic intraoperative intraperitoneal chemoperfusion followed by postoperative intravenous platinum-based chemotherapy in patients with platinum-sensitive recurrent epithelial ovarian cancer.Int. J. Cancer. 2015; 136: 699-708
Cytoreductive surgery and intraoperative hyperthermic intraperitoneal chemotherapy with paclitaxel: a clinical and pharmacokinetic study.Ann. Surg. Oncol. 2008; 15: 1183-1192
Pharmacokinetics of concomitant cisplatin and paclitaxel administered by hyperthermic intraperitoneal chemotherapy to patients with peritoneal carcinomatosis from epithelial ovarian cancer.Br. J. Cancer. 2015; 112: 306-312
A phase I dose-escalation of hyperthermic intraoperative intraperitoneal chemotherapy (HIPEC) carboplatin for the frontline treatment of advanced ovarian cancer.J. Clin. Oncol. 2018; 36: 5554
Peritoneal carcinomatosis treated with cytoreductive surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for advanced ovarian carcinoma: a French multicentre retrospective cohort study of 566 patients.Eur. J. Surg. Oncol. 2013; 39: 1435-1443
Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) for persistent and recurrent advanced ovarian carcinoma: a multicenter, prospective study of 246 patients.Ann. Surg. Oncol. 2012; 19: 4052-4058
- Cascales-Campos P.A.
- et al.
Treatment of microscopic disease with hyperthermic intraoperative intraperitoneal chemotherapy after complete cytoreduction improves disease-free survival in patients with stage IIIC/IV ovarian cancer.Ann. Surg. Oncol. 2014; 21: 2383-2389
- Munoz-Casares F.C.
- et al.
Peritonectomy procedures and HIPEC in the treatment of peritoneal carcinomatosis from ovarian cancer: long-term outcomes and perspectives from a high-volume center.Eur. J. Surg. Oncol. 2016; 42: 224-233
Cytoreduction (peritonectomy procedures) combined with Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in advanced ovarian cancer: retrospective Italian multicenter observational study of 511 cases.Ann. Surg. Oncol. 2017; 24: 914-922
Secondary cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for recurrent epithelial ovarian cancer: a multi-institutional study.BJOG. 2012; 119: 800-809
Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for first relapse of ovarian cancer.Anticancer Res. 2015; 35: 4997-5005
Treatment of peritoneal carcinomatosis from ovarian cancer by surgical cytoreduction and hyperthermic intraperitoneal chemotherapy (HIPEC).Minerva Chir. 2014; 69: 27-35
Cytoreductive surgery plus HIPEC in platinum-sensitive recurrent ovarian cancer patients: a case-control study on survival in patients with two year follow-up.Gynecol. Oncol. 2012; 127: 502-505
- Cascales-Campos P.A.
- et al.
The role of hyperthermic intraperitoneal chemotherapy using paclitaxel in platinum-sensitive recurrent epithelial ovarian cancer patients with microscopic residual disease after cytoreduction.Ann. Surg. Oncol. 2015; 22: 987-993
Primary peritoneal serous carcinoma treated by cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy. A multi-institutional study of 36 patients.Eur. J. Surg. Oncol. 2013; 39: 742-747
Hyperthermic intraperitoneal chemotherapy with cisplatin and paclitaxel in advanced ovarian cancer: a multicenter prospective observational study.J. Gynecol. Oncol. 2015; 26: 54-61
Long-term survival for platinum-sensitive recurrent ovarian cancer patients treated with secondary cytoreductive surgery plus Hyperthermic Intraperitoneal Chemotherapy (HIPEC).Ann. Surg. Oncol. 2016; 23: 1660-1665
Incidence and management of pancreatic leaks after splenectomy with distal pancreatectomy performed during primary cytoreductive surgery for advanced ovarian, peritoneal and fallopian tube cancer.Gynecol. Oncol. 2009; 112: 496-500
The incidence of major complications after the performance of extensive upper abdominal surgical procedures during primary cytoreduction of advanced ovarian, tubal, and peritoneal carcinomas.Gynecol. Oncol. 2010; 119: 38-42
Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis.J. Clin. Oncol. 2002; 20: 1248-1259
What is the optimal goal of primary cytoreductive surgery for bulky stage IIIC epithelial ovarian carcinoma (EOC)?.Gynecol. Oncol. 2006; 103: 559-564
Improved progression-free and overall survival in advanced ovarian cancer as a result of a change in surgical paradigm.Gynecol. Oncol. 2009; 114: 26-31
Guidelines and selection criteria for secondary cytoreductive surgery in patients with recurrent, platinum-sensitive epithelial ovarian carcinoma.Cancer. 2006; 106: 1933-1939
The addition of extensive upper abdominal surgery to achieve optimal cytoreduction improves survival in patients with stages IIIC-IV epithelial ovarian cancer.Gynecol. Oncol. 2006; 103: 1083-1090
Relative influences of tumor volume before surgery and the cytoreductive outcome on survival for patients with advanced ovarian cancer: a prospective study.Gynecol. Oncol. 2003; 90: 390-396
The effect of primary cytoreduction on outcomes of patients with FIGO stage IIIC ovarian cancer stratified by the initial tumor burden in the upper abdomen cephalad to the greater omentum.Gynecol. Oncol. 2010; 116: 351-357
Cytoreductive surgery and HIPEC in recurrent epithelial ovarian cancer: a prospective randomized phase III study.Ann. Surg. Oncol. 2015; 22: 1570-1575
Brief report about the role of hyperthermic intraperitoneal chemotherapy in a prospective randomized phase 3 study in recurrent ovarian cancer from Spiliotis et al.Int. J. Gynecol. Cancer. 2017; 27: 246-247
Statement of the AGO Kommission Ovar, AGO Study Group, NOGGO, AGO Austria and AGO Switzerland regarding the use of Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in ovarian cancer.Geburtshilfe Frauenheilkd. 2016; 76: 147-149
Hyperthermic intraperitoneal chemotherapy in ovarian cancer.N. Engl. J. Med. 2018; 378: 230-240
Randomized trial of hyperthermic intraperitoneal chemotherapy (HIPEC) in women with primary advanced peritoneal, ovarian, and tubal cancer.J. Clin. Oncol. 2017; 35: 5520
The role of heated intraperitoneal chemotherapy (HIPEC) in ovarian cancer: hope or hoax?.Ann. Surg. Oncol. 2012; 19: 3998-4000
- Chiva L.M.
- Gonzalez-Martin A.
A critical appraisal of hyperthermic intraperitoneal chemotherapy (HIPEC) in the treatment of advanced and recurrent ovarian cancer.Gynecol. Oncol. 2015; 136: 130-135
- Vergote I.
- Chiva L.
- du Bois A.
Hyperthermic intraperitoneal chemotherapy in ovarian cancer.N. Engl. J. Med. 2018; 378: 1362-1363
- Gore M.
- du Bois A.
- Vergote I.
Intraperitoneal chemotherapy in ovarian cancer remains experimental.J. Clin. Oncol. 2006; 24: 4528-4530
Intraperitoneal chemotherapy in patients with advanced ovarian cancer: the con view.Oncologist. 2008; 13: 410-414
Safety and antitumor activity of anti-PD-1 antibody, nivolumab, in patients with platinum-resistant ovarian cancer.J. Clin. Oncol. 2015; 33: 4015-4022
Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer.N. Engl. J. Med. 2016; 375: 2154-2164
Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial.Lancet Oncol. 2014; 15: 852-861
Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer.N. Engl. J. Med. 2012; 366: 1382-1392
OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer.J. Clin. Oncol. 2012; 30: 2039-2045
Neoadjuvant chemotherapy and primary debulking surgery utilization for advanced-stage ovarian cancer at a comprehensive cancer center.Gynecol. Oncol. 2016; 140: 436-442
An analysis of patients with bulky advanced stage ovarian, tubal, and peritoneal carcinoma treated with primary debulking surgery (PDS) during an identical time period as the randomized EORTC-NCIC trial of PDS vs neoadjuvant chemotherapy (NACT).Gynecol. Oncol. 2012; 124: 10-14
Neoadjuvant chemotherapy in ovarian cancer revisited.Ann. Oncol. 2016; 27: i30-i32
Low-dose pressurized intraperitoneal aerosol chemotherapy (PIPAC) as an alternative therapy for ovarian cancer in an octogenarian patient.Anticancer Res. 2015; 35: 2309-2314
Activity of pressurized intraperitoneal aerosol chemotherapy (PIPAC) with cisplatin and doxorubicin in women with recurrent, platinum-resistant ovarian cancer: preliminary clinical experience.Gynecol. Oncol. 2014; 132: 307-311
A UNICANCER phase III trial of hyperthermic intra-peritoneal chemotherapy (HIPEC) for colorectal peritoneal carcinomatosis (PC): PRODIGE 7.J. Clin. Oncol. 2018; 36: LBA3503